| Type | Public |
|---|---|
| Traded as | BSE: 500674 NSE: AVENTIS |
| Industry | Pharmaceuticals |
| Founded | May 1956 |
| Headquarters | Mumbai, India |
| Key people | Dr. Shailesh Ayyangar (MD) [1] |
| Products | Prescription and over-the-counter drugs for thrombosis, cardiovascular disease, diabetes, central nervous system disorders, oncology and internal medicine, vaccines (list...) |
| Revenue | 1,085.50 crore (US$206.25 million) (2009-2010) |
| Employees | 1,840 (2010) [2] |
| Website | www.aventispharmaindia.com |
Aventis Pharma Limited (BSE: 500674|NSE: AVENTIS), headquartered in Mumbai, is a part of Sanofi-Aventis group.[3] Sanofi-Aventis and its 100% subsidiary Hoechst AG, are the major shareholders of Aventis Pharma Limited. Its manufacturing portfolio contains medicines for several therapeutic areas including cardiovascular, thrombotic, metabolic disorders, oncology, disorders of the central nervous system, internal medicine.[4] Its primarily business is medicines in the dosage forms of liquid injectibles, tablets, capsules, ointments, drops and syrup.[5] In July 2003, company launched Lantus, the world's first and only once a day insulin.[6]
Aventis Pharma Limited was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited.[7] Over the years, its name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited and Hoechst Marion Roussel Limited.